ATP11A: A Potential Drug Target and Biomarker (G23250)

Target Name: ATP11A

NCBI ID: G23250

ATP11A

ATP11A: A Potential Drug Target and Biomarker

ATP11A is a gene that encodes a protein known as ATP11A_HUMAN. This protein plays a critical role in the regulation of the blood-brain barrier, which is responsible for controlling the movement of substances into and out of the brain. ATP11A_HUMAN has been shown to be involved in a number of physiological processes, including the regulation of ion and water transport across the blood-brain barrier, as well as the maintenance of the brain's cellular structure and function.

In addition to its role in the brain, ATP11A_HUMAN has also been shown to play a key role in the regulation of various physiological processes throughout the body. For example, studies have shown that ATP11A_HUMAN is involved in the regulation of blood pressure, blood flow, and cell signaling.

Given its involvement in so many important physiological processes, it is not surprising that ATP11A_HUMAN has become a focus of interest for researchers as a potential drug target. By targeting this protein, researchers hope to be able to gain new insights into the underlying mechanisms that regulate the brain and body, and to develop new treatments for a variety of diseases.

One of the key challenges in developing new treatments for diseases is identifying the underlying mechanisms that cause the disease. This is because many diseases are caused by the buildup of excessive or harmful substances in the body, which can disrupt the delicate balance of physiological processes that keep the body functioning. In order to understand the underlying mechanisms of a disease, it is important to have a clear understanding of the regulation of the body's physiological processes.

ATP11A_HUMAN is an important part of this process, as it plays a key role in the regulation of the blood-brain barrier. The blood-brain barrier is a specialized barrier that separates the brain from the surrounding blood, and helps to protect the brain from harmful substances that could cause damage. However, the blood-brain barrier is not very selective, and can allow a wide variety of substances to enter the brain. ATP11A_HUMAN is involved in the regulation of the movement of substances across this barrier, ensuring that only certain substances are able to enter the brain and cause harm.

In addition to its role in the blood-brain barrier, ATP11A_HUMAN is also involved in the regulation of various other physiological processes. For example, studies have shown that ATP11A_HUMAN is involved in the regulation of blood pressure, blood flow, and cell signaling. This suggests that this protein may be a useful target for researchers who are looking for new treatments for conditions that involve these processes, such as heart disease, cancer, and neurological disorders.

Another potential benefit of targeting ATP11A_HUMAN is that it may also have the potential to address a number of ethical concerns associated with the development of new drugs. The development of new drugs often requires the use of animals, which can be a source of suffering and controversy. By targeting ATP11A_HUMAN, researchers may be able to develop new treatments that are more ethically and sustainably sourced, as well as those that are more effective and less toxic.

In conclusion, ATP11A_HUMAN is a gene that encodes a protein that plays a critical role in the regulation of the blood-brain barrier and various other physiological processes. Its potential as a drug target makes it an attractive target for researchers who are looking for new treatments for a variety of diseases. While further research is needed to fully understand the role of ATP11A_HUMAN in the regulation of the body, its potential as a drug target is an exciting area of study that could lead to new and more effective treatments for a wide range of diseases.

Protein Name: ATPase Phospholipid Transporting 11A

Functions: Catalytic component of a P4-ATPase flippase complex which catalyzes the hydrolysis of ATP coupled to the transport of aminophospholipids, phosphatidylserines (PS) and phosphatidylethanolamines (PE), from the outer to the inner leaflet of the plasma membrane (PubMed:25315773, PubMed:25947375, PubMed:26567335, PubMed:29799007, PubMed:30018401). Does not show flippase activity toward phosphatidylcholine (PC) (PubMed:34403372). Contributes to the maintenance of membrane lipid asymmetry with a specific role in morphogenesis of muscle cells. In myoblasts, mediates PS enrichment at the inner leaflet of plasma membrane, triggering PIEZO1-dependent Ca2+ influx and Rho GTPases signal transduction, subsequently leading to the assembly of cortical actomyosin fibers and myotube formation (PubMed:29799007). May be involved in the uptake of farnesyltransferase inhibitor drugs, such as lonafarnib

The "ATP11A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ATP11A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets